E-resources
PDF-
Siegel, Stuart E.; Advani, Anjali; Seibel, Nita; Muffly, Lori; Stock, Wendy; Luger, Selina; Shah, Bijal; DeAngelo, Daniel J.; Freyer, David R.; Douer, Dan; Johnson, Rebecca H.; Hayes‐Lattin, Brandon; Lewis, Mark; Jaboin, Jerry J.; Coccia, Peter F.; Bleyer, Archie
American journal of hematology, October 2018, Volume: 93, Issue: 10Journal Article
For young adults with acute lymphoblastic leukemia, pediatric‐based regimens are likely to provide the following when compared to hyper‐CVAD regimens: better disease control, less hospitalization time, diminished acute toxicities, decreased financial cost, more quality‐adjusted life years, and fewer adverse late effects, such as infertility, myelodysplasia, and second malignant neoplasms. There are also reasons to expect less cardiac and cognitive dysfunction after pediatric regimens. The improved quality and quantity of life associated with pediatric regimens renders them preferable to hyper‐CVAD regimens for the treatment of Philadelphia‐negative B‐precursor or T‐cell acute lymphoblastic leukemia and lymphoblastic lymphoma in young adults.
